Vaxart Inc's (NASDAQ:VXRT) has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost immunogenicity. 

• Study participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021.  
• All seven previously immunized participants with the oral norovirus vaccine-elicited similar immune responses to norovirus as the five subjects who did not receive an initial oral vaccine dose.  
• Serum antibody blocking titer 50, a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts. 
• Antibody secreting B cell responses to norovirus VP1 measured seven days post-boost were no different from those in subjects receiving the vaccine for the first time. 
• Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between vaccinated and unvaccinated subjects.
• Price Action: VXRT shares are 5.06% at $8.63 during the market session on the last check Thursday.
• Image by Wilfried Pohnke from Pixabay